ArticleAnimals : an open access journal from MDPI2026
Canine Hemangiosarcoma Cell Lines In Vitro Platform Captures Morphological, Functional, and Molecular Diversity.
Article in Animals : an open access journal from MDPI, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Both canine hemangiosarcoma and human angiosarcoma are aggressive malignancies characterized by clinical and molecular heterogeneity. Current in vitro models rely on individual cell lines, failing to capture this biological complexity. We established a standardized 2D in vitro platform comprising a panel of three canine primary splenic hemangiosarcoma cell lines (EMN009, EMN011, EMN017) and one patient-matched brain metastasis (EMN010) evaluated in parallel. Using gold-standard assays-morphometrics, growth, migration and tube-formation assays-alongside disease-relevant transcriptomic and microRNA profiling, we characterized this multi-line system under harmonized conditions. Neoplastic lines shared a robust core angiogenic signature of 42 overexpressed genes linked to VEGF, AGE-RAGE, and S1P signaling, and a 47-gene cancer stem cell engine enriched in the Hippo/YAP1 pathway. Transcriptomic clustering divided the lines into slower-growing primary tumors (EMN009/EMN011) and highly angiogenic phenotypes (EMN017/EMN010). Isogenic comparison revealed that the metastatic EMN010 uniquely upregulates STAT signaling and peptidyl-tyrosine phosphorylation. MicroRNA profiling demonstrated a global downregulation of tumor-suppressors miR-126-5p and miR-452-5p, unleashing VEGFA-driven angiogenesis, while visceral hemangiosarcoma biomarker miR-214-3p was significantly upregulated. Conversely, miR-10b and miR-133-3p expression varied across lines, reflecting ongoing clonal evolution. This integrated platform successfully recapitulates hemangiosarcoma heterogeneity, providing a reliable, standardized framework for comparative oncology and targeted pathophysiological studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.